About Oceana Therapeutics
Oceana Therapeutics is a Healthcare company based in Edison (United States) founded in 2008, and was acquired by Salix Pharmaceuticals in November 2011. Therapeutics are developed for colorectal, gastroenterology, and urological diseases. Oceana Therapeutics has raised $3 million across 3 funding rounds from investors including Salix Pharmaceuticals, Kelso & Company and NEA. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is OCEANA THERAPEUTICS INC. Its competitors include Ironwood Pharma, Alcresta and Seed; 3 of its 3 listed competitors have raised funding.
Company details
Oceana Therapeutics was founded in 2008 in Edison, United States, with a focus on the healthcare sector. Specialty therapeutics for colorectal, gastroenterology, and urological conditions have been developed. The portfolio includes Deflux, used for treating vesicoureteral reflux in pediatric patients, and Solesta, applied as a nonsurgical option for fecal incontinence. Acquisition by Salix Pharmaceuticals occurred in November 2011.
- Headquarters Edison, United States
- Stage Acquired
- SectorsHealthcare
- Website oceanathera.com
- Social LinkedIn
- Acquired by Salix Pharmaceuticals (Nov 2011)
- Legal Name Oceana Therapeutics Inc
- Total Equity Funding$3M (USD)
in 3 rounds
- Latest Funding Round$3M (USD), Series A
May 2009
- InvestorsSalix Pharmaceuticals
& 4 more
- Acquired bySalix Pharmaceuticals
(Nov 2011)
Funding Insights of Oceana Therapeutics
Oceana Therapeutics has successfully raised a total of $3M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in May 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 3
- Last Round Series A — $3M
- Investors Count 4
All 3 funding rounds of Oceana Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2009 | $3M | Series A | – | – | – |
| Apr 2009 | Series A | – | – | ||
| Sep 2008 | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Oceana Therapeutics
Oceana Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Salix Pharmaceuticals, Kelso & Company and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | kelso.com | New York, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
| quakerbio.com | ||||
Specialty pharmaceutical company focusing on prevention and treatment of gastrointestinal (GI) disorders. | 1989 | salix.com | Bridgewater, United States |
Investor details for Oceana Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Oceana Therapeutics
4 dated milestones of Oceana Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Oceana Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $3.0M.
- Exit Acquired by Salix Pharmaceuticals.
Competitors of Oceana Therapeutics
Oceana Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Alcresta and Seed.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| alcresta.com | 2011 | Newton, United States | $95.89M | 52 | Enzyme-based products for gastrointestinal disorders are developed using immobilization technology. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | Synbiotics are developed for simulating the gut microbiome. |
Detailed competitors of Oceana Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Oceana Therapeutics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Oceana Therapeutics
Oceana Therapeutics was founded in 2008.
Oceana Therapeutics is headquartered in Edison, United States. It is registered at Edison, New Jersey, United States.
Oceana Therapeutics is a funded company, having raised a total of $3M across 3 funding rounds to date.
Oceana Therapeutics was founded in 2008 in Edison, United States, with a focus on the healthcare sector. Specialty therapeutics for colorectal, gastroenterology, and urological conditions have been developed. The portfolio includes Deflux, used for treating vesicoureteral reflux in pediatric patients, and Solesta, applied as a nonsurgical option for fecal incontinence. Acquisition by Salix Pharmaceuticals occurred in November 2011.
Oceana Therapeutics's top competitors include Ironwood Pharma, Seed and Alcresta.
Oceana Therapeutics has 5 investors. Key investors include Salix Pharmaceuticals, Kelso & Company, NEA, Domain Associates, and Quaker Partners.
Oceana Therapeutics operates through Oceana Therapeutics Inc.
Yes. Oceana Therapeutics was acquired by Salix Pharmaceuticals in November 2011.